Clinical Trial Update: Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) [Phase 2]

View source ↗

Summary

Phase 2B extension study of ataluren in Duchenne/Becker muscular dystrophy was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Becker Muscular Dystrophy
• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2020-07-15